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Abstract
Despite continuous improvements in therapeutic protocols, cancer-related mortality
is still one of the main problems facing public health. The main cause of treatment
failure is multi-drug resistance (MDR: simultaneous insensitivity to different anti-
cancer agents), the underlying molecular and biological mechanisms of which
include the activity of ATP binding cassette (ABC) proteins and drug
compartmentalisation in cell organelles. We investigated the expression of the main
ABC proteins and the role of cytoplasmic vacuoles in the MDR of six hepatocellular
carcinoma (HCC) cell lines, and confirmed the accumulation of the yellow anti-
cancer drug sunitinib in giant (four lines) and small cytoplasmic vacuoles of
lysosomal origin (two lines). ABC expression analyses showed that the main ABC
protein harboured by all of the cell lines was PGP, whose expression was not
limited to the cell membrane but was also found on lysosomes. MTT assays
showed that the cell lines with giant lysosomes were more resistant to sorafenib
treatment than those with small lysosomes (p,0.01), and that verapamil incubation
can revert this resistance, especially if it is administered after drug pre-incubation.
The findings of this study demonstrate the involvement of PGP-positive lysosomes
in drug sequestration and MDR in HCC cell lines. The possibility of modulating this
mechanism using PGP inhibitors could lead to the development of new targeted
strategies to enhance HCC treatment.
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Introduction
The resistance of tumour cells to anti-cancer agents continues to be a major cause
of treatment failure in cancer patients. Multi-drug resistance (MDR) describes a
situation in which cancer cells become simultaneously resistant to different drugs
that have no obvious similarities in terms of structure or mechanism of action [1].
Over the last 20 years, research has revealed that MDR is multifactorial and
involves decreased drug accumulation and/or increased efflux, an increased
detoxification capacity, improved DNA repair, alterations in drug target
susceptibility, apoptotic defects, and the induction of alternative growth factor
signalling and epithelial to mesenchymal transition [1]. One of the best-
characterised mechanisms of MDR occurs via cytoprotective drug pumps located
into the plasma membrane that actively efflux various cytotoxic compounds [2]
thus decreasing intra-cellular drug concentrations. These pumps include the ATP
binding cassette (ABC) transporter family of 48 proteins that have been divided
into seven sub-groups (A-G) on the basis of their sequence homology [3] and
lung resistance-related protein (LRP) [4]. It has been fond that the poly-specific
drug transporters ABCB1 (P-glycoprotein, PGP), ABCC1 (multidrug resistance-
associated protein 1, MRP1), ABCG2 (breast cancer resistance protein, BCRP)
and the ribonucleoprotein LRP are over-expressed in various types of cancer [4–
7], and a number of studies have investigated the possibility of using conventional
drugs or siRNA to inhibit ABC and LRP proteins in order to overcome MDR in
myelomas and solid tumours such as ovarian, renal and hepatocellular carcinomas
(HCCs) [8–13]. However, although promising in vitro, conventional drug
therapies have been found to have highly toxic side effects in vivo due to
physiological pump blockade and the competitive inhibition of cytochrome P-450
enzymes leading to increased plasma drug concentrations [14]. Second- and
third-generation inhibitors have developed in an attempt to overcome these
drawbacks but, although they have fewer side effects, they are also less efficacious
[15].
Since the finding of MDR proteins on cell membranes, researchers have begun
to investigate the role of cell compartments and organelles in the chemoresistance
process and, using various MDR breast, colon, renal and ovarian cancer cell lines,
a number of groups have shown that the intra-cellular compartmentalisation of
anti-cancer drugs can reduce their effectiveness by limiting access to intra-cellular
drug targets [16–18].
Similarly, we have recently demonstrated the presence in the same primary
human HCC of three tumour cell clones with different degrees of in vitro
chemoresistance [19] and, taking advantage of the yellow colour of sunitinib,
noticed that the most drug-resistant cell clone (Hcc-1) showed drug accumulation
in intra-cellular vacuoles during in vitro culture.
The aim of this study was to investigate the nature of these drug-accumulating
vacuoles and their possible role in the process of drug resistance, and we have
observed that tyrosine kinase inhibitors (TKIs) - including sorafenib, the only oral
drug approved for the treatment of advanced HCC - accumulate in cell lysosomes
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and documented the fact that this can influence the chemosensitivity of HCC
cells.
Materials and Methods
Cell cultures
Five commercial human HCC cell lines (HuH7, HepG2, Hep3B, PLC/PFR/5 and
SNU475), purchased from the Japanese Collection of Research Bioresources
(JCRB) or the American Type Cell Collection (ATCC), and one primary HCC cell
line, obtained in our laboratory (Hcc-1) [19], were cultured in
IMDM+GlutaMAX supplemented with 10% FBS, 1% penicillin-streptomycin and
1% non-essential amino acids (Invitrogen, Life Technologies, Milan, Italy) on
collagen type I-coated flasks or multi-well plates. The cells were maintained at
37 C˚ in a humidified incubator containing 5% CO2.
Sunitinib accumulation
In order to verify drug absorption, the cells were incubated with sunitinib
(formerly SU11248, Pfizer, New York, NY, USA), which can be easily visualised in
culture because of its yellow colour and green fluorescence. The cells were kept in
culture with sunitinib 12 mM for two hours and the drug’s localisation was
evaluated by means of microscopy.
Vesicle localisation
The intra- or inter-cellular localisation of the vesicles with sunitinib accumulation
was determined by means of immunostaining with a primary monoclonal
antibody against the b1 integrin (CD29, Becton Dickinson, Franklyn Lakes, NJ,
USA), which is expressed by all the studied cell lines, for one hour at 37 C˚. After
washing, the cells were stained with a secondary anti-mouse TRITC antibody
diluted 1:50 for 30 minutes at 37 C˚, and then 10 mg/ml of Hoechst 33342 (Sigma-
Aldrich, St.Louis, MO, USA) was added for 20 minutes for nuclear staining. The
cell images were acquired and analysed using a Leica DM IRE2 fluorescence
microscope (Leica Microsystem, Wetzlar, Germany).
Oil-red-O staining
In order to exclude the possibility that the vesicles were mere lipid droplets
accumulating sunitinib by diffusion, we used Oil-red-O staining. Cells cultured in
6-well plates were fixed with 10% formalin for one hour at room temperature
(RT) and washed three times with 60% 2-propanol (Carlo Erba, Milan, Italy).
After drying, 2 mg/mL of Oil-red-O (Sigma-Aldrich) in 2-propanol was added for
10 minutes at RT, the cells were washed four times with distilled water, and
images were acquired using an Eclipse TS100 microscope (Nikon, Tokyo, Japan).
Lysosomes and Drug Resistance in HCC
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Sunitinib accumulation after weak base cell treatment
To test the lysosomal origin of cell vesicles, we re-evaluated drug distribution in
the presence of ammonium chloride (NH4Cl) in culture medium. In fact, weak
bases, buffering the lysosomal pH, are able to inhibit the accumulation of cationic
amphiphilic drugs (such as sunitinib) in lysosomes [17]. Cells were seeded in a 24-
well plate and treated as follow:
Well 1) NH4Cl 3 mM for 30 minutes followed by sunitinib 12 mM+NH4Cl
3 mM for further 90 minutes.
Well 2) sunitinib 12 mM for 60 minutes followed by sunitinib 12 mM+NH4Cl
3 mM for further 90 minutes.
Cells were monitored by means of optical microscopy and pictures were taken
before treatment, and after the first and second incubation.
Immunofluorescence staining of cell vesicles
Tumour cells were directly fixed with 70% ethanol in 96-well plates, permeabilised
and blocked with a solution of 10% goat serum and 0.1% Tween 20 (Sigma-
Aldrich) for 20 minutes at RT, and then stained with polyclonal rabbit anti-
vacuole membrane protein 1 (VMP1), anti-human peroxisomal membrane
protein 70 (PMP70), monoclonal mouse anti-protein disulfide isomerase (PDI)
(all from Millipore, Billerica, MA, USA) or anti-lysosome-associated membrane
protein-1 (LAMP-1) (Becton Dickinson) for two hours at RT. After washing, the
cells were incubated with FITC-conjugated goat anti-rabbit or anti-mouse
antibody for one hour in the dark at RT and, after further washing, DAPI was
added for nuclear staining. The images were acquired and analysed using a Leica
DM IRE2 microscope.
Western Blot
Whole cell extracts were prepared using a lysis buffer containing 20 mM Tris-HCl
(pH 7.8), 140 mM NaCl, 1 mM EDTA, 0.5% NP40, 1 mM phenylmethylsulfonil
fluoride, and complete protease inhibitor mixture (Roche Diagnostics,
Mannheim, Germany). Cell lysates were first passed 5 times through a 30.5-gauge
needle to disrupt the nuclei, then incubated at 4 C˚ for 15 minutes and finally
centrifuged at 13000 rpm for 15 minutes at 4 C˚. Total protein concentration was
determined according to Lowry’s method [20].
Samples were resolved on 8% polyacrylamide gel, transferred to supported
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA), and the
filters were saturated in blocking solution (10 mM Tris (pH 7.4), 154 mM NaCl,
1% BSA, 10% horse serum, and 0.075% Tween-20). The anti-human LAMP-1
(1:250) (Millipore, Darmstadt, Germany) antibody was incubated overnight at
4 C˚. We also determined the expression of the housekeeping protein b-Tubulin III
(Sigma-Aldrich) in each sample. Detection was performed with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Dako Cytomation,
Carpinteria, CA, USA), followed by enhanced chemiluminescence (ECL)
Lysosomes and Drug Resistance in HCC
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development (Amersham Biosciences, Piscataway, NJ, USA). Pre-stained
molecular weight markers (Bio-Rad Laboratories, Hercules, CA, USA) were run
on each gel. Bands were visualized by autoradiography using Amersham
Hyperfilm Images of bands were obtained using the CanoScan LiDE60 Scanner
(Canon, Milan, Italy) and the Canon ScanGear Software. Densitometric analyses
were performed using ImageJ software (http://rsbweb.nih.gov/ij/).
Time-lapse experiments
Time-lapse experiments were used to follow the vesicles’ kinetics and fate. The
cells were incubated with sunitinib 12 mM in complete medium (without phenol
red) in a 35 mm diameter Petri dish for two hours in order to allow the cells to
store the drug in their vesicles, and were then transferred to a Nikon Biostation
IM. Pictures were taken every 10 minutes for seven hours.
Flow cytometry
Tumour cells were detached from the flasks using TripLE Express (Invtrogen),
resuspended and incubated in PBS supplemented with 4% fetal calf serum, 4%
mouse serum and 0.1% NaN3 for 20 minutes at 4 C˚ in order to saturate the
unspecific bound sites, and were then stained with mouse anti-ABCG2, anti-LRP,
anti-MRP1 and anti-PGP antibodies for 20 minutes at 4 C˚ (Becton Dickinson);
after washing, a secondary PE-conjugated goat-anti-mouse antibody (GAM-PE,
Becton Dickinson) was added for 159 in the dark at 4 C˚. In order to exclude dead
cells from the analysis, 7-aminoactinomycin D (7-AAD, Becton Dickinson) was
added to each tube.
The cells were immunophenotyped as previously described [19]. Briefly, they
were stained with primary fluorochrome-conjugated EpCAM, CD133, CD44,
CD56 and CD90 antibodies, and the data were acquired and analysed using a
FACSCantoII flow cytometer and FACSDiva software (Becton Dickinson).
Fluorescence microscopy
Cultured cells were stained in 96-well plates using the same primary monoclonal
antibodies as those used for the flow cytometry analysis (anti-ABCG2, LRP, MRP1
and PGP) following the protocol for cell organelle staining. The wells were
mounted, and the images taken using a Leica DM IRE2 microscope.
Chemoresistance assays
Cell line chemoresistance was evaluated using sorafenib (LC Laboratories,
Woburn, MA, USA) or sunitinib in combination with the PGP inhibitor
verapamil [21] at a concentration of 20 mM, the highest non-toxic concentration
on the basis of previous titration assays (data not shown).
In order to quantify sorafenib resistance, the cells underwent an MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) assay in
Lysosomes and Drug Resistance in HCC
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triplicate. The cells were seeded in 96-well plates at a concentration of 8000 cells/
well in complete medium, and allowed to recover for one night at 37 C˚. Sorafenib
was administered as follows:
1) Sorafenib 0–50 mM alone for 24 hours.
2) One hour of pre-incubation with verapamil 20 mM followed by 24 hours of
co-incubation with verapamil 20 mM and sorafenib 0–50 mM.
3) One hour of pre-incubation with sorafenib 0–50 mM followed by 24 hours of
co-incubation with verapamil 20 mM and sorafenib 0–50 mM.
After drug treatment, the cells were incubated with 5 mg/ml MTT solution for
four hours at 37 C˚ and, after medium removal, the MTT salts were dissolved with
DMSO for five minutes; viability was evaluated on the basis of 550 nm absorption
using a Xenius plate reader (Safas, Munich, Germany). IC50 values were calculated
by means of non-linear regression analysis using GraphPad Prism version 5.0
software (GraphPad Software, San Diego, CA, USA).
Moreover, we implemented another MTT assay on HepG2 and SNU475, as
representative cell lines with giant and small lysosomes, using NH4Cl 3 mM
instead of verapamil with the same scheme reported above.
Similarly, all cell lines cultured in 24-well plates were treated with sunitinib
12 mM (corresponding to the lowest detected IC50) using the same treatment
protocols as those used for sorafenib in order to monitor cell death visually. The
cells were monitored by means of optical microscopy and pictures were taken
before treatment, after pre-incubation, and after two and 12 hours of treatment.
Statistical analyses
The data were statistically analysed using Friedman’s test or Student’s t test as
required, and GraphPad Prism version 5.0 software. P values of ,0.05 were
considered statistically significant.
Results
Sunitinib accumulation
Under basal conditions, the HCC cell lines showed different patterns of vesicle
expression: the HepG2 and Hcc-1 lines had 1–2 large cytoplasmic vacuoles per
cell; the HuH7 and PLC/PRF/5 lines had 1–2 medium-sized vesicles; and the
Hep3B and SNU475 had no visible vesicles. After sunitinib incubation, large
yellow vesicles were visible in the HepG2, Hcc-1, HuH7 and PLC/PRF/5 cells,
whereas the Hep3B and SNU475 cells showed only very small yellow cell vesicles
(Fig. 1).
Vesicle localisation
Fig. 2 clearly shows the intra-cellular localisation of green vesicles (sunitinib
autofluorescence) after staining the cytoplasmic membranes of HCC cells with b1
Lysosomes and Drug Resistance in HCC
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Fig. 1. Sunitinib accumulation in cytoplasmic vesicles of HCC cell lines. Representative pictures of cell
lines cultured without (left) or with (right) sunitinib 12 mM. Cytoplasmic vesicles are visible in the Hep3B and
SNU475 cells only after sunitinib incubation. Original magnification 20x.
doi:10.1371/journal.pone.0114787.g001
Lysosomes and Drug Resistance in HCC
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integrin. No Oil-red-O staining of the cytoplasmic vesicles in any of the cell lines
was observed (Fig. 3), thus ruling out the possibility that they were mere lipid
droplets. Furthermore, cell pre-incubation with NH4Cl did not allow sunitinib
accumulation in cell vesicles, while sunitinib-loaded vesicles released the drug
after NH4Cl addition in culture medium, thus suggesting a lysosomal origin of cell
vesicles (S1 Figure). Moreover, we also observed an increased number of
lysosomes in Hcc-1, HepG2, PLC/PRF/5 and HuH7 after NH4Cl incubation.
Immunofluorescence staining, Western blot and time-lapse
experiments
The intra-cellular vesicles stained positively for LAMP-1 (Fig. 4) but negatively for
VMP1, PMP70 and PDI (data not shown), thus indicating their lysosomal nature.
Western blot analysis confirmed a higher expression of LAMP-1 in those cell lines
carrying giant lysosomes as compared to those characterized by small lysosomes
(p,0.05) (Fig. 5).
Fig. 2. Cytoplasmic vesicle localisation. Fluorescence microscopy images confirming intra-cellular vesicle
localisation. (A) Hcc-1, (B) HepG2, (C) Hep3B, and (D) SNU475 cells. Sunitinib autofluorescence (green),
CD29 staining (red) and Hoechst 33342 nuclear staining (blue). Original magnification 40x.
doi:10.1371/journal.pone.0114787.g002
Lysosomes and Drug Resistance in HCC
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The time-lapse experiments showed that some of the vesicles retained their
content for seven hours, whereas others fused with the cell membrane and
released their contents outside the cells. This behaviour is consistent with that of
secretory lysosomes [22]. It was also possible to observe that some of these
lysosomes stored new sunitinib, thus enhancing their fluorescence (Fig. 6 and S1
Video).
MDRP expression and cell immunophenotyping
By means of flow cytometry, we observed that ABCG2 was expressed on the
membrane of only 9% of Hcc-1 cells, and was almost absent from the surface of
the cells in the other lines. ABCB1 was highly expressed only on the surface of
HepG2 (58%), Hcc-1 (18%) and HuH7 cells (13%), but expressed on only about
3% of PLC/PRF/5 cells. The other MDRPs were expressed at levels of ,2%
(Fig. 7). Immunofluorescence staining revealed that, when expressed, ABCG2,
LRP and MRP1 were localised at cell membrane level, whereas PGP (ABCB1) also
stained lysosomes (Fig. 8).
Immunophenotyping revealed higher levels of the epithelial stem cell markers
EpCAM and CD133 on Hcc-1, HepG2, Huh7 and PLC/PRF/5 cells, whereas
SNU475 had high levels of the mesenchymal markers CD44, CD56 and CD90.
Hep3B cells had an intermediate phenotype (Table 1).
Fig. 3. Oil-red-O staining. The cytoplasmic vesicles of all of the cell lines were negative for Oil-red-O staining (white arrows), ruling out that are lipid
droplets. (A) Hcc-1, (B) HepG2, (C) PLC/PRF/5, (D) HuH7, (E) Hep3B, (F) SNU475, and (G) bone marrow adipocyte (positive control). Original magnification
20x.
doi:10.1371/journal.pone.0114787.g003
Lysosomes and Drug Resistance in HCC
PLOS ONE | DOI:10.1371/journal.pone.0114787 December 10, 2014 9 / 20
Chemoresistance assays
Different treatments with sunitinib and sorafenib in combination with verapamil
were tested in order to define the best in vitro treatment model.
Interestingly, the cell lines with giant lysosomes (Hcc-1, HepG2, PLC/PRF/5
and HuH7) had higher IC50 values than the lines with small lysosomes (Hep3B
and SNU475) (Fig. 9A). As expected, pre-incubation with verapamil increased the
efficacy of sorafenib in comparison with sorafenib alone in all of the cell lines
(P,0.05) (Fig. 9B). However, unexpectedly, pre-treatment with sorafenib was
more efficacious than pre-treatment with verapamil in the cell lines with giant
lysosomes (P,0.05), whereas no difference was observed in the Hep3B and
SNU475 cell lines (Fig. 9B).
Regarding experiments in which we substituted verapamil with NH4Cl, we
observed a lower IC50 in cell cultures pre-incubated with both NH4Cl or
Fig. 4. Immunofluorescence staining of cell organelles. Vesicle membranes (arrowheads) stained positive
for anti-LAMP1 antibody (green). All of the other antibodies against organelle proteins were negative (data not
shown). (A) Hcc-1, (B) HepG2, (C) PLC/PRF/5, (D) HuH7, (E) Hep3B, and (F) SNU475. Nuclei were stained
with DAPI (blue). Original magnification 20x.
doi:10.1371/journal.pone.0114787.g004
Lysosomes and Drug Resistance in HCC
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sunitinib, whereas, differently from ‘‘verapamil experiments’’, no differences were
detected between the two pre-treatment schemes (S2 Figure).
Finally, 12-hour cell mortality, monitored by optical microscopy, was greater in
the cells pre-incubated with sunitinib than in those pre-incubated with verapamil
(Fig. 10).
Discussion
Drug resistance, which involves several different pathways, is the main mechanism
responsible for treatment failure and death among cancer patients, but its
underlying molecular and biological mechanisms are still unclear. However,
during a recent study [19], we observed that, although generated from the same
primary tumour, different HCC cell lines were differently sensitive to the tyrosine
kinase inhibitor sunitinib and that this sensitivity directly correlated with the
membrane expression of the drug’s target. We also observed that the highly
Fig. 5. Western blot. A) Whole cell extracts were analyzed for LAMP-1 protein expression levels by Western
blot using b tubulin as loading control. 1) Hcc-1, 2) HepG2, 3) PLC/PRF/5, 4) HuH7, 5) Hep3B and 6)
SNU475. B) Relative quantification of LAMP-1 expression. The four HCC cell lines carrying giant lysosomes
(Hcc-1, HepG2, PLC/PRF/5 and HuH7) showed higher LAMP-1 expressions as compared to Hep3B and
SNU475 (showing small lysosomes).
doi:10.1371/journal.pone.0114787.g005
Lysosomes and Drug Resistance in HCC
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resistant primary cell line Hcc-1 showed giant yellow vesicles in the cytoplasm
after incubation with sunitinib, which is auto-fluorescent, thus indicating drug
accumulation. A similar finding has been more recently reported by Date et al.
[23], who demonstrated the accumulation of tamoxifen in the intra-cytoplasmic
vacuoles of HepG2 cells. We therefore investigated the nature of these organelles
and their role in inducing drug-resistance in six HCC cell lines routinely cultured
in our laboratory.
During in vitro HCC cell culture in the presence of sunitinib, the cell lines with
more epithelial characteristics (i.e. Hcc-1, HepG2, PLC/PRF/5 and HuH7)
developed giant intra-cellular vacuoles, whereas those with mesenchymal features
(i.e. Hep3B and SNU475) presented small vacuoles. Furthermore, these vacuoles
had a lysosomal origin and intra-cellular localisation, unlike that recently
described in breast cancer cells in which chemoresistance to mitoxantrone was
associated with an extra-cellular localisation of vesicles [16]. However, our
findings are in line with those of Gotink et al. and Yamagishi et al., who have
described the involvement of lysosomes in drug sequestration due to the MDRP
activity in renal and colon cancer cell lines [17, 18]. Moreover, as already observed
by Goldman et al., we found an increment of the number and dimension of
lysosomes after NH4CL incubation due to the extensive ion-trapping-based
accumulation of lysosomotropic weak bases in these organelles [24].
With regard to MDRPs, our flow cytometry and fluorescence microscopy
analyses revealed that ABCG2, ABCC1 and MVP were rarely expressed and only
on the plasma membrane of the HCC cell lines, thus suggesting their involvement
in the classic mechanism of drug resistance that involves drug expulsion from the
cytoplasm to extra-cellular space. The P-glycoprotein (PGP-ABCB1) was also
Fig. 6. Time-lapse experiments. Over a period of seven hours it is possible to see that some lysosomes released their content outside the cells (top row,
white circles), whereas others started to accumulate new sunitinib in their lumens (bottom row, white arrowheads).
doi:10.1371/journal.pone.0114787.g006
Lysosomes and Drug Resistance in HCC
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present on both giant and small lysosomes, thus supporting the involvement of
PGP in lysosome-based drug sequestration in HCC cells.
Interestingly, we found a direct correlation between the size of the PGP-positive
lysosomes and resistance to sorafenib or sunitinib treatment: the Hcc-1, HepG2,
Fig. 7. Flow cytometry evaluation of MDRPs. LRP and MRP1 were not detected by means of flow
cytometry in any cell line. ABCG2 was expressed on only 9% of the Hcc-1 cells, and was almost absent on the
surface of the other cell lines. ABCB1 (PGP) was highly expressed on the plasma membrane of HepG2
(58%), Hcc-1 (18%) and HuH7 cells (13%), but expressed on only about 3% of PLC/PRF/5 cells. Left column
negative controls; middle column ABCG2 expression; right column PGP expression.
doi:10.1371/journal.pone.0114787.g007
Lysosomes and Drug Resistance in HCC
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Fig. 8. Immunofluorescence staining of MDRPs. Representative pictures of MDRP staining in HCC cell
lines. The expression and localisation of MDRPs was different in the various HCC cell lines: ABCG2, LRP and
MRP1 were localised on the membrane of the few groups of cells on which they were expressed, whereas
PGP was mainly found in the cell cytoplasm, particularly on the membrane of intra-cellular vesicles. Nuclei
stained with DAPI (blue). Original magnification 20x.
doi:10.1371/journal.pone.0114787.g008
Table 1. Immunophenotyping.
Marker Hcc-1 HepG2 PLC/PRF/5 HuH7 Hep3B SNU475
EpCAM 90 80 10 90 50 1
CD133 1 14 70 60 2 9
CD44 33 3 2 4 10 98
CD56 5 1 1 4 14 99
CD90 1 1 3 5 2 99
The table shows the mean percentage of cells positive for each marker.
doi:10.1371/journal.pone.0114787.t001
Lysosomes and Drug Resistance in HCC
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PLC/PRF/5 and HuH7 cell lines, harbouring giant lysosomes and expressing
higher level of LAMP-1, showed statistically significant higher IC50 values than the
SNU475 and Hep3B cell lines, harbouring small lysosomes and a lower level of
LAMP-1. As expected, treatment with verapamil, a PGP inhibitor, enhanced the
chemosensitivity of all of the cell lines to tyrosine kinase inhibitors.
Unexpectedly, pre-incubation with sorafenib before co-incubation with
verapamil increased drug efficacy in the HCC cell lines with giant lysosomes. We
hypothesise that, during the pre-incubation phase, anti-cancer drugs are trapped
in PGP-positive lysosomes and that blocking PGP activity by means of subsequent
Fig. 9. Chemoresistance assays. A) When treated with sorafenib, the cell lines with giant PGP-positive
lysosomes (Hcc-1, HepG2, PLC/PRF/5 and HuH7) showed higher IC50 values than those with normal
lysosomes (Hep3B and SNU475) (p,0.01). B) The HCC cell lines were incubated with different
concentrations of sorafenib in order to verify their chemosensitivity (green lines). The cells with larger
cytoplasmic vesicles were characterised by a curve with a sort of plateau of viability at sorafenib
concentrations of between 5 and 20 mmol. One hour of verapamil pre-treatment used to inhibit ABC proteins
before co-incubation with sorafenib and sunitinib increased the chemosensitivity of all of the cell lines (black
curves). *p,0.01 green vs. black curves. One hour of sorafenib pre-treatment (red lines) before co-incubation
with sorafenib and sunitinib enhanced treatment efficacy in comparison with verapamil pre-treatment in the
cell lines carrying giant lysosomes. 1p,0.05 red vs. black curves.
doi:10.1371/journal.pone.0114787.g009
Lysosomes and Drug Resistance in HCC
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drug/verapamil co-incubation would allow drug diffusion from the culture
medium and lysosome into the cytoplasm, thus increasing intra-cellular drug
concentrations (Fig. 11). On the contrary, the pre-treatments with both sunitinib
or NH4CL showed the same increment in drug efficacy as compare to drug alone.
This could be due to the absence of verapamil action on cell membrane PGP
activity which leads to drug accumulation in the cytoplasm with a strong impact
on cell viability.
In line with our data, Sun et al. [25] have found that verapamil concentrations
of 6–10 mmol/L can completely reverse MDR in malignant tumour cells by
inhibiting PGP and enhancing tumour cell sensitivity to chemotherapy; however,
unfortunately, when serum verapamil concentration reaches 1–2 mmol/L, cardiac
toxicity limits the drug’s clinical application. Nevertheless, as verapamil undergoes
Fig. 10. Sunitinib treatments. Representative pictures of the effect of sunitinib treatments on the HepG2
(with giant lysosomes) and SNU475 cell lines (with normal lysosomes). The rows show the treatment
conditions: 1) Sunitinib 12 mM alone for 12 hours; 2) One hour of pre-incubation with verapamil 20 mM
followed by the co-incubation of verapamil 20 mM and sunitinib 12 mM for 12 hours; 3) One hour of pre-
incubation with sunitinib 12 mM followed by the co-incubation of verapamil 20 mM and sunitinib 12 mM for 12
hours. It can be seen that, in both cell lines, cell death after 12 hours’ treatment was greater in the cells pre-
treated with sunitinib.
doi:10.1371/journal.pone.0114787.g010
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extensive hepatic first pass metabolism [26], it is theoretically feasible that the side
effect of the drug can be avoided by using targeted intra-hepatic injections in
combination with chemoembolisation. According to recent experimental reports,
the efficacy and safety of such protocols are promising in patients with HCC [27–
28].
In conclusion, our study shows that the resistance of HCC cells to multi-
targeted tyrosine kinase inhibitors such as sorafenib and sunitinib is mediated by
Fig. 11. Hypothesised mechanism of the enhanced efficacy of drug pre-treatment before verapamil administration and PGP blockade. A) HCC cells
expressing active PGP can expel a drug (e.g. sunitinib) from the cytoplasm or store it in lysosomes. B) Blocking PGP with verapamil before the co-
administration sunitinib and verapamil allows the drugs to enter the cell and diffuse into cytoplasm/nucleus. C) If sunitinib is used for pre-treatment, it is
stored in giant lysosomes and, after the co-administration of sunitinib and verapamil and subsequent PGP blockade, the drugs can enter the cytoplasm/
nucleus from both extra-cellular space and the lysosomes.
doi:10.1371/journal.pone.0114787.g011
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lysosomal sequestration (which is particularly evident in HCC cells with epithelial
features), a mechanism that can be modulated by MDRP blockers such as
verapamil. Our findings therefore pave the way for in vivo studies aimed at
exploring the feasibility of the sequential administration of tyrosine kinase
inhibitors and verapamil as a means of improving the chemosensitivity of liver
cancer.
Supporting Information
S1 Figure. NH4Cl cell treatment. Representative pictures of cell lines cultured
with NH4Cl 3 mM for 30 minutes (A) followed by sunitinib 12 mM+NH4Cl
3 mM for further 90 minutes (B) (Well 1) or with sunitinib12 mM for 60 minutes
(C) followed by sunitinib 12 mM+NH4Cl 3 mM for further 90 minutes (D) (well
2). Original magnification 20x.
doi:10.1371/journal.pone.0114787.s001 (TIF)
S2 Figure. MTT assay with sunitinib and NH4Cl. Both HepG2 and SNU475 cell
lines showed a decreased IC50 when they were pre-incubated with sunitinib or
NH4Cl as compared to the treatment with sunitinib alone (P,0.05 and P,0.01,
respectively). (SUN5sunitinib alone; PRE NH4Cl5pre-incubation with NH4Cl;
PRE SUN5pre-incubation with sunitinib).
doi:10.1371/journal.pone.0114787.s002 (TIF)
S1 Video. Time-lapse experiments. Time-lapse video of HepG2 cells loaded with
sunitinib 12 mM for two hours before being transferred to a Nikon Biostation IM.
The pictures were taken every 10 minutes for seven hours. Original magnification
20x.
doi:10.1371/journal.pone.0114787.s003 (ZIP)
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